Curon makes cuts and focuses on top line growth
This article was originally published in Clinica
Executive Summary
Curon Medical, which develops proprietary products for the treatment of gastrointestinal disorders, is cutting 17% of its workforce, as well as making further cuts in its operating expenses. The measures come just a week after the company's president and CEO, John Morgan, resigned. The Sunnyvale, California-based company's chairman, Michael Berman, is assuming the position of CEO on an interim basis.